Daewoong Pharmaceutical Co., Ltd. Announces Positive Safety Review for Bersiporocin
Daewoong Pharmaceutical announced that its idiopathic pulmonary fibrosis (IPF) drug candidate Bersiporocin received a recommendation to continue its global Phase 2 clinical trial.
The third Independent Data Monitoring Committee (IDMC) review confirmed the safety of Bersiporocin, with 94 patients enrolled out of 102 planned across Korea and the U.S.
The IDMC conducted an in-depth evaluation of interim safety data from 89 enrolled patients and found no significant safety concerns that would impact the trial's continuation.
- 94 participants enrolled, representing approximately 92% of the target population (102 patients)
- The study is progressing as planned
Author's summary: Daewoong Pharmaceutical's Bersiporocin continues global Phase 2 trial.
More News
- SJHN Daily: Celebrini Named NHL First Star of the Week
- Battlefield 6 REDSEC battle royale to officially launch soon
- Acting in Self-Defense – Communications of the ACM
- Mystery of The Ocean's Missing Plastic a Step Closer to Being Solved
- Acres.com to collaborate with UA System’s Fryar Center - Talk Business & Politics
- Jon Jones Strikes Again at Tom Aspinall, Reminding Fans of His Lightning-Fast Gane Win | MiddleEasy
- SLO County Touts Improved Public Safety with Opening of New Communications Center | News Channel 3-12
- Importing beef is not the solution | GABEL
- Queer Issues are Human Issues - The McGill Daily
- Congress Eyes New Cyber and Communications Powers for the National Guard